Mirum Pharmaceuticals Inc Total Liabilities
Mirum Pharmaceuticals Inc total liabilities. Based on the latest financial reports, Mirum Pharmaceuticals Inc (MIRM) has total liabilities worth $648.42 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See how many days can Mirum Pharmaceuticals Inc fund operations to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Mirum Pharmaceuticals Inc (2018–2025)
Total liabilities of Mirum Pharmaceuticals Inc from 2018 to 2025. This chart illustrates how Mirum Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Mirum Pharmaceuticals Inc to evaluate the company's liquid asset resilience ratio.
Mirum Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Mirum Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Greatwall Computer Shenzhen Co Ltd
SHE:000066
|
China | CN¥22.25 Billion |
|
Kite Realty Group Trust
NYSE:KRG
|
USA | $3.47 Billion |
|
Vipshop Holdings Limited
NYSE:VIPS
|
USA | $35.12 Billion |
|
WinWay Technology Co. Ltd
TW:6515
|
Taiwan | NT$1.98 Billion |
|
Amlogic Shanghai Co Ltd
SHG:688099
|
China | CN¥1.14 Billion |
|
ViTrox Corporation Bhd
KLSE:0097
|
Malaysia | RM482.53 Million |
|
CSN Mineração S.A
SA:CMIN3
|
Brazil | R$26.79 Billion |
|
EVN AG
VI:EVN
|
Austria | €4.44 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Mirum Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see MIRM total asset value.
Liquidity & Leverage Metrics
Mirum Pharmaceuticals Inc Total Liabilities Ratios Explained
Mirum Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.67 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.73 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mirum Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mirum Pharmaceuticals Inc (2018–2025)
The table below shows the annual total liabilities of Mirum Pharmaceuticals Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $528.12 Million | +18.65% |
| 2024-12-31 | $445.11 Million | +11.85% |
| 2023-12-31 | $397.95 Million | +88.72% |
| 2022-12-31 | $210.87 Million | +20.88% |
| 2021-12-31 | $174.44 Million | +153.66% |
| 2020-12-31 | $68.77 Million | +320.27% |
| 2019-12-31 | $16.36 Million | -73.73% |
| 2018-12-31 | $62.30 Million | -- |
About Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille … Read more